Picking value is hard in the biotech bubble
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The rise and rise of the biotechnology sector of the stock market apparently knows no bounds. Chiroscience has seen its shares effectively double since last month's announcement that it may have a more advanced form of British Biotech's Marimastat anti-cancer drug. After a further 20p rise to 520p yesterday, its market capitalisation is now pounds 429m. This for a company which has never made a profit and which on Tuesday proudly announced a turnover of just pounds 5m for last year.
Others biotechs too have seen spectacular share price rises, if not quite on the Alpine scale of Chiroscience. The huge head of steam building up behind the sector is being driven by hopes that British Biotech, the acknowledged leader, will announce later this month that the latest tests on Marimastat are positive and bring it closer to the market. Prices are being maintained by wildly optimistic claims from certain brokers. Last month, for instance, Greig Middleton suggested that the "fair value" of British Biotech shares could be pounds 70 by early next year, more than double their current price of just below pounds 30. A year ago, they were worth less than pounds 5.
The current market in biotechnology stocks is taking on all the characteristics of a bubble, where investors are blind to the risks and keep piling in because the rewards promise returns beyond the dreams of avarice. Picking real value from the sector is akin to seeking needles in a haystack.The certainty that some of these companies will be abject failures should never be far from investors' thoughts.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments